The updated guideline includes 25 recommendations, emphasizing risk stratification and minimizing unnecessary evaluations for low-risk patients. New guidance incorporates urine-based tumor markers for ...
"I would say, talk to each other. Talk to other men about it. You are not the only one leaking," says Vanita Gaglani, RPT. In this video, Vanita Gaglani, RPT, gives advice to men with ...
"I'm always trying new things. I feel like, once you decide that this is the way you have to do it and stick with that forever, that's when you immediately become irrelevant," says Amy E. Krambeck, MD ...
Panelists discuss how the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) encompasses multiple therapeutic options including novel hormonal agents, ...
“In the setting of widespread metastatic progression or failure, we typically prefer more systemic therapy with metastasis-directed therapy for symptomatic sites,” says Kate H. Gessner, MD, PhD. In ...
Panelists discuss how radiopharmaceuticals like lutetium-177 prostate-specific membrane antigen (PSMA) may be preferred over systemic therapy in patients with prostate cancer who have high PSMA ...
Experts discuss the standard of care and the use of intravesical chemotherapy in the treatment of non–muscle-invasive bladder cancer (NMIBC).
“The primary end point is progression-free survival, and the secondary end points are overall survival, objective response rates, duration of response, and safety.” In this video, Francesca ...
The Neuspera pSNM device achieved significant symptom reduction in UUI, with 84.2% of patients experiencing a 50% or greater reduction in urgent leaks. The device offers an alternative to traditional ...
Panelists discuss how the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) encompasses multiple therapeutic options including novel hormonal agents, ...
The CLEAR trial demonstrated lenvatinib plus pembrolizumab's superior efficacy over sunitinib in advanced renal cell carcinoma, with robust response rates and significant tumor shrinkage. Sustained ...
Nivolumab plus cabozantinib significantly improved PFS, OS, and ORR compared with sunitinib in patients with advanced RCC. The combination therapy showed a median PFS of 16.4 months vs 8.3 months for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback